384 related articles for article (PubMed ID: 21126615)
1. Effect of the metabolic syndrome and hyperuricemia on outcome in patients with coronary artery disease (from the Bezafibrate Infarction Prevention Study).
Brodov Y; Behar S; Boyko V; Chouraqui P
Am J Cardiol; 2010 Dec; 106(12):1717-20. PubMed ID: 21126615
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
[TBL] [Abstract][Full Text] [Related]
3. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
4. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
[TBL] [Abstract][Full Text] [Related]
5. Serum uric acid for risk stratification of patients with coronary artery disease.
Brodov Y; Chouraqui P; Goldenberg I; Boyko V; Mandelzweig L; Behar S
Cardiology; 2009; 114(4):300-5. PubMed ID: 19776568
[TBL] [Abstract][Full Text] [Related]
6. Hyperuricemia and the metabolic syndrome in Hangzhou.
Cai Z; Xu X; Wu X; Zhou C; Li D
Asia Pac J Clin Nutr; 2009; 18(1):81-7. PubMed ID: 19329400
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of combining serum uric acid and C-reactive protein for risk stratification of patients with coronary artery disease (Bezafibrate Infarction Prevention [BIP] study).
Brodov Y; Behar S; Goldenberg I; Boyko V; Chouraqui P
Am J Cardiol; 2009 Jul; 104(2):194-8. PubMed ID: 19576345
[TBL] [Abstract][Full Text] [Related]
8. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
[TBL] [Abstract][Full Text] [Related]
9. Association between serum uric acid, metabolic syndrome and microalbuminuria in previously untreated essential hypertensive patients.
Rodilla E; Pérez-Lahiguera F; Costa JA; González C; Miralles A; Moral D; Pascual JM
Med Clin (Barc); 2009 Jan; 132(1):1-6. PubMed ID: 19174057
[TBL] [Abstract][Full Text] [Related]
10. Uric acid as a link between renal dysfunction and both pro-inflammatory and prothrombotic state in patients with metabolic syndrome and coronary artery disease.
Zapolski T; Waciński P; Kondracki B; Rychta E; Buraczyńska MJ; Wysokiński A
Kardiol Pol; 2011; 69(4):319-26. PubMed ID: 21523662
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome does not increase angiographic restenosis rates after drug-eluting stent implantation.
Canibus P; Faloia E; Piva T; Muçai A; Serenelli M; Perna GP; Boscaro M; Piva R
Metabolism; 2008 May; 57(5):593-7. PubMed ID: 18442619
[TBL] [Abstract][Full Text] [Related]
12. Impact of the metabolic syndrome on the clinical outcomes of non-clinically diagnosed diabetic patients with acute coronary syndrome.
Feinberg MS; Schwartz R; Tanne D; Fisman EZ; Hod H; Zahger D; Schwammethal E; Eldar M; Behar S; Tenenbaum A
Am J Cardiol; 2007 Mar; 99(5):667-72. PubMed ID: 17317369
[TBL] [Abstract][Full Text] [Related]
13. Hyperuricemia and metabolic syndrome in Taiwanese children.
Lee MS; Wahlqvist ML; Yu HL; Pan WH
Asia Pac J Clin Nutr; 2007; 16 Suppl 2():594-600. PubMed ID: 17724000
[TBL] [Abstract][Full Text] [Related]
14. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease.
Solymoss BC; Bourassa MG; Lespérance J; Levesque S; Marcil M; Varga S; Campeau L
Coron Artery Dis; 2003 May; 14(3):207-12. PubMed ID: 12702923
[TBL] [Abstract][Full Text] [Related]
15. Uric acid: a surrogate of insulin resistance in older women.
Chen LK; Lin MH; Lai HY; Hwang SJ; Chiou ST
Maturitas; 2008 Jan; 59(1):55-61. PubMed ID: 18082342
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Tenenbaum A; Motro M; Fisman EZ; Schwammenthal E; Adler Y; Goldenberg I; Leor J; Boyko V; Mandelzweig L; Behar S
Circulation; 2004 May; 109(18):2197-202. PubMed ID: 15123532
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of multiple coronary risk factors in Punjabi Bhatia community: Jaipur Heart Watch-3.
Gupta R; Sarna M; Thanvi J; Rastogi P; Kaul V; Gupta VP
Indian Heart J; 2004; 56(6):646-52. PubMed ID: 15751521
[TBL] [Abstract][Full Text] [Related]
18. Association between serum uric acid and perioperative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery.
Dunkelgrun M; Welten GM; Goei D; Winkel TA; Schouten O; van Domburg RT; van Gestel YR; Flu WJ; Hoeks SE; Bax JJ; Poldermans D
Am J Cardiol; 2008 Oct; 102(7):797-801. PubMed ID: 18805100
[TBL] [Abstract][Full Text] [Related]
19. Relationship between hyperuricemia and metabolic syndrome.
Chen LY; Zhu WH; Chen ZW; Dai HL; Ren JJ; Chen JH; Chen LQ; Fang LZ
J Zhejiang Univ Sci B; 2007 Aug; 8(8):593-8. PubMed ID: 17657863
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
